Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations.
Ascher S, Kravitz R, Scherzer R, Berry J, de Lemos J, Estrella M, Tancredi D, Killeen A, Ix J, Shlipak M. Incorporating Individual-Level Treatment Effects and Outcome Preferences Into Personalized Blood Pressure Target Recommendations. Journal Of The American Heart Association 2024, 13: e033995. PMID: 39136305, DOI: 10.1161/jaha.124.033995.Peer-Reviewed Original ResearchNet benefitsSPRINT participantsIndividual-level treatment effectsPositive net benefitsBlood pressureIndividual treatment effectsTargeted recommendationsTreatment effectsSimulated preferencesRisk of adverse eventsAdverse eventsCognitive impairmentPreference weightsRisk differenceDecision-making frameworkAE riskPatient riskSprintSimulation benefitsParticipantsPredicted riskHigh riskCox modelBP loweringRiskIntensive Blood Pressure Lowering in Individuals With Low Diastolic Blood Pressure and Elevated Troponin Levels in SPRINT
Smith C, Berry J, Scherzer R, de Lemos J, Nambi V, Ballantyne C, Kravitz R, Killeen A, Ix J, Shlipak M, Ascher S. Intensive Blood Pressure Lowering in Individuals With Low Diastolic Blood Pressure and Elevated Troponin Levels in SPRINT. Journal Of The American Heart Association 2024, 13: e032493. PMID: 38497469, PMCID: PMC11010028, DOI: 10.1161/jaha.123.032493.Peer-Reviewed Original ResearchConceptsLower diastolic blood pressureDiastolic blood pressureHs-cTnTElevated hs-cTnTIntensive BPBlood pressureIntensive blood pressure loweringBaseline diastolic blood pressureCardiovascular diseaseElevated troponin levelsComposite end pointOptimal BP targetAll-cause deathBlood pressure loweringElevated systolic BPIntensive BP controlCardiovascular disease riskTroponin levelsBP loweringBP targetsMortality benefitPressure loweringSubgroup analysisBP controlSystolic BP